Optic Nerve Injury in Obstructive Sleep Apnea Patients
Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obs
| Condition(s) | Obstructive Sleep Apnea (OSA), Ischemic Optic Neuropathy/Optic Nerve Stroke |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Ischemic optic neuropathy (ION) is damage to the optic nerve caused by ischemia and hypoxia of the optic nerve due to an impairment of the blood supply to the optic nerve from the arteries. Obstructive Sleep Apnea Hypoventilation Syndrome (OSAHS) is a sleep-breathing disorder characterized by recurrent upper airway obstruction and apnea during sleep, leading to recurrent intermittent hypoxemia with fragmented sleep and daytime sleepiness. Due to the lack of accurate methods to evaluate blood flow, the correlation between the two is unclear and uncertain. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University and categorize them into mild, moderate, and severe OSA groups according to their apnea-hypopnea index (AHI). Participants will undergo a ba |
| Who can participate | Inclusion Criteria: 1. Patients aged between 18 and 80 years. 2. Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)(apnea-hypopnea index≥5/h). 3. First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA. 4. Ability and willingness to provide informed consent for participation in the study. Exclusion Criteria: 1. History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results. 2. Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases. 3. Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart fa |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | Nanjing Medical University |
| Locations | Nanjing, Jiangsu, China |
| Start date | 2025-01-01 |
| NCT ID | NCT06748703 |
| Official listing | https://clinicaltrials.gov/study/NCT06748703 |